ATE475094T1 - Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung - Google Patents

Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung

Info

Publication number: ATE475094T1
Authority: AT; Austria
Prior art keywords: leptin; prediposition; treatment; determining; human beings
Prior art date: 2001-10-22

Application number

AT02793811T

Other languages

English (en)

Inventor

Alex M Depaoli

Elif Oral

Simeon I Taylor

A Garg

Original Assignee

Amgen Inc

Us Gov Health & Human Serv

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-22

Filing date

2002-10-22

Publication date

2010-08-15

2002-10-22 Application filed by Amgen Inc, Us Gov Health & Human Serv, Univ Texas filed Critical Amgen Inc

2010-08-15 Application granted granted Critical

2010-08-15 Publication of ATE475094T1 publication Critical patent/ATE475094T1/de

Links

206010024604 Lipoatrophy Diseases 0.000 title 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 9
102000016267 Leptin Human genes 0.000 abstract 5
108010092277 Leptin Proteins 0.000 abstract 5
229940039781 leptin Drugs 0.000 abstract 5
206010049287 Lipodystrophy acquired Diseases 0.000 abstract 2
208000006132 lipodystrophy Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)

AT02793811T 2001-10-22 2002-10-22 Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung ATE475094T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33639401P	2001-10-22	2001-10-22
PCT/US2002/033875 WO2003034996A2 (en)	2001-10-22	2002-10-22	Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Publications (1)

Publication Number	Publication Date
ATE475094T1 true ATE475094T1 (de)	2010-08-15

Family

ID=23315890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02793811T ATE475094T1 (de)	2001-10-22	2002-10-22	Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung

Country Status (14)

Country	Link
US (7)	US7183254B2 (de)
EP (2)	EP2219031B1 (de)
JP (7)	JP2005506994A (de)
AT (1)	ATE475094T1 (de)
AU (1)	AU2002359288B2 (de)
CA (1)	CA2464277C (de)
DE (1)	DE60237100D1 (de)
DK (2)	DK1444516T3 (de)
ES (2)	ES2418954T3 (de)
MX (1)	MXPA04003773A (de)
PL (1)	PL214862B1 (de)
PT (1)	PT2219031E (de)
SI (1)	SI2219031T1 (de)
WO (1)	WO2003034996A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE475094T1 (de) *	2001-10-22	2010-08-15	Amgen Inc	Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
DK1814590T4 (da)	2004-11-01	2014-02-24	Amylin Pharmaceuticals Llc	Behandling af obesitet og beslægtede sygdomme.
US8227408B2 (en) *	2005-09-07	2012-07-24	Neurotez, Inc.	Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070066512A1 (en) *	2005-09-12	2007-03-22	Dominique Verhelle	Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2008048691A2 (en) *	2006-10-18	2008-04-24	Amylin Pharmaceuticals, Inc.	Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
KR20110028457A (ko)	2008-05-21	2011-03-18	뉴로테즈 인코포레이티드	신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
WO2009149379A2 (en) *	2008-06-05	2009-12-10	Regents Of The University Of Michigan	Use of leptin for the treatment of fatty liver diseases and conditions
CA2742600A1 (en)	2008-11-04	2010-05-14	Nikolaos Tezapsidis	Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US20110218141A1 (en) *	2010-03-03	2011-09-08	Hamrick Mark W	Leptin therapy to increase muscle mass and to treat muscle wasting conditions
MX349054B (es)	2010-09-28	2017-07-07	Aegerion Pharmaceuticals Inc	Leptinas altamente solubles.
DK2729160T3 (da)	2011-07-08	2019-07-01	Aegerion Pharmaceuticals Inc	Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
CN111529535A (zh)	2012-09-27	2020-08-14	儿童医学中心公司	用于治疗肥胖症的化合物和其使用方法
WO2014203074A2 (en)	2013-06-21	2014-12-24	Alize Pharma Sas	Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
PT3074033T (pt)	2013-11-26	2019-02-08	Childrens Medical Ct Corp	Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en)	2014-04-03	2017-07-27	The Children's Medical Center Corporation	Hsp90 inhibitors for the treatment of obesity and methods of use thereof
JP2015205846A (ja) *	2014-04-22	2015-11-19	出光興産株式会社	レプチン分泌促進剤
TWI580690B (zh) *	2014-08-25	2017-05-01		The use of multidipins for the manufacture of pharmaceutical compositions for in vivo multipurpose effects
TWI824372B (zh)	2015-10-12	2023-12-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
DK3509624T3 (da)	2016-09-12	2023-11-13	Amryt Pharmaceuticals Inc	Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
SMT202500283T1 (it)	2018-04-06	2025-09-12	Regeneron Pharma	Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
GB202100311D0 (en) *	2021-01-11	2021-02-24	Univ Court Of The Univ Of Aberdeen	Treatment for Lipodystrophy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en)	1995-01-20	1998-10-27	University Of Washington	Materials and methods for determining ob protein in a biological sample
US5532336A (en)	1995-01-31	1996-07-02	Eli Lilly And Company	Anti-obesity proteins
US5563244A (en)	1995-01-31	1996-10-08	Eli Lilly And Company	Anti-obesity proteins
US5559208A (en)	1995-01-31	1996-09-24	Eli Lilly And Company	Anti-obesity proteins
US5552522A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
US5569744A (en)	1995-01-31	1996-10-29	Eli Lilly And Company	Anti-obesity proteins
US5525705A (en)	1995-01-31	1996-06-11	Eli Lilly And Company	Anti-obesity proteins
US5580954A (en)	1995-01-31	1996-12-03	Eli Lilly And Company	Anti-obesity proteins
JPH11501297A (ja)	1995-01-31	1999-02-02	イーライ・リリー・アンド・カンパニー	抗肥満症タンパク質
US5605886A (en)	1995-01-31	1997-02-25	Eli Lilly And Company	Anti-obesity proteins
US5563243A (en)	1995-01-31	1996-10-08	Eli Lilly And Company	Anti-obesity proteins
US5574133A (en)	1995-01-31	1996-11-12	Eli Lilly And Company	Anti-obesity proteins
US5567678A (en)	1995-01-31	1996-10-22	Eli Lilly And Company	Anti-obesity proteins
US5569743A (en)	1995-01-31	1996-10-29	Eli Lilly And Company	Anti-obesity proteins
US5594104A (en)	1995-01-31	1997-01-14	Eli Lilly And Company	Anti-obesity proteins
US5552523A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
US5521283A (en)	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
EP0725079A1 (de)	1995-01-31	1996-08-07	Eli Lilly And Company	Proteine gegen die Fettleibigkeit
US5691309A (en)	1995-01-31	1997-11-25	Eli Lilly And Company	Anti-obesity proteins
US5567803A (en)	1995-01-31	1996-10-22	Eli Lilly And Company	Anti-obesity proteins
US5563245A (en)	1995-01-31	1996-10-08	Eli Lilly And Company	Anti-obesity proteins
US5554727A (en)	1995-01-31	1996-09-10	Eli Lilly And Company	Anti-obesity proteins
US5552524A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
US5594101A (en)	1995-03-03	1997-01-14	Eli Lilly And Company	Anti-obesity proteins
US5719266A (en)	1995-03-17	1998-02-17	Eli Lilly And Company	Anti-obesity proteins
EP0736599A3 (de)	1995-04-03	1996-12-11	Takeda Chemical Industries Ltd	Das Obesitätsgen der Ratte, sein Genprodukt und dessen Herstellung
AU5539596A (en)	1995-04-06	1996-10-23	Amylin Pharmaceuticals, Inc.	Anti-obesity agents
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
ES2093593T1 (es)	1995-05-05	1997-01-01	Hoffmann La Roche	Proteinas obesas (ob) recombinantes.
GB9509164D0 (en)	1995-05-05	1995-06-28	Smithkline Beecham Plc	Novel compounds
EP0826045A1 (de)	1995-05-08	1998-03-04	Chiron Corporation	Nukleinsäuren zur behandlung von feltsucht
CA2221824A1 (en)	1995-05-26	1996-11-28	Eli Lilly And Company	Rhesus ob protein and dna
WO1996040912A1 (en)	1995-06-07	1996-12-19	Amgen Inc.	Ob protein compositions and method
AU6284896A (en)	1995-06-22	1997-01-22	Eli Lilly And Company	Obesity protein intermediates and their preparation and use
AU695934B2 (en) *	1995-06-30	1998-08-27	Eli Lilly And Company	Methods for treating diabetes
WO1997006816A1 (en)	1995-08-17	1997-02-27	Amgen Inc.	Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997016550A1 (en)	1995-11-02	1997-05-09	Bristol-Myers Squibb Company	Polypeptide fragments derived from the obese gene product
CA2236163A1 (en)	1995-11-22	1997-05-29	Amgen Inc.	Methods of increasing lean tissue mass using ob protein compositions
WO1997020933A2 (en)	1995-12-06	1997-06-12	Schering Corporation	MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
AU2670897A (en)	1996-04-04	1997-10-29	Amgen, Inc.	Fibulin pharmaceutical compositions and related methods
BR9709529A (pt)	1996-06-06	1999-08-10	Smithkline Beecham P L C Socie	Fragmentos de leptina (proteína ob)
US5922678A (en) *	1996-06-28	1999-07-13	Eli Lilly And Company	Methods for treating diabetes
WO1998008512A1 (en)	1996-08-30	1998-03-05	Amgen Inc.	Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
WO1998016545A1 (en)	1996-10-11	1998-04-23	Eli Lilly And Company	Therapeutic proteins
EP1835030A1 (de)	1996-12-20	2007-09-19	Amgen, Inc.	ob-Fusionsprotein enthaltende Zusammensetzungen und Verfahren
CA2344623A1 (en)	1998-10-02	2000-04-13	Amgen Inc.	Method to determine a predisposition to leptin treatment
EP1151102B1 (de) *	1999-02-12	2006-04-19	Amgen Inc.	Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US6258932B1 (en) *	1999-08-09	2001-07-10	Tripep Ab	Peptides that block viral infectivity and methods of use thereof
JP2001199887A (ja) *	1999-11-10	2001-07-24	Takeda Chem Ind Ltd	体重増加抑制剤
ATE475094T1 (de) *	2001-10-22	2010-08-15	Amgen Inc	Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
US6899892B2 (en) *	2001-12-19	2005-05-31	Regents Of The University Of Minnesota	Methods to reduce body fat

2002
- 2002-10-22 AT AT02793811T patent/ATE475094T1/de not_active IP Right Cessation
- 2002-10-22 DK DK02793811.7T patent/DK1444516T3/da active
- 2002-10-22 MX MXPA04003773A patent/MXPA04003773A/es active IP Right Grant
- 2002-10-22 CA CA2464277A patent/CA2464277C/en not_active Expired - Lifetime
- 2002-10-22 ES ES10165256T patent/ES2418954T3/es not_active Expired - Lifetime
- 2002-10-22 JP JP2003537565A patent/JP2005506994A/ja active Pending
- 2002-10-22 EP EP10165256.8A patent/EP2219031B1/de not_active Expired - Lifetime
- 2002-10-22 SI SI200231031T patent/SI2219031T1/sl unknown
- 2002-10-22 DK DK10165256.8T patent/DK2219031T3/da active
- 2002-10-22 DE DE60237100T patent/DE60237100D1/de not_active Expired - Lifetime
- 2002-10-22 EP EP02793811A patent/EP1444516B1/de not_active Expired - Lifetime
- 2002-10-22 PL PL374301A patent/PL214862B1/pl unknown
- 2002-10-22 PT PT101652568T patent/PT2219031E/pt unknown
- 2002-10-22 ES ES02793811T patent/ES2350924T3/es not_active Expired - Lifetime
- 2002-10-22 AU AU2002359288A patent/AU2002359288B2/en not_active Expired
- 2002-10-22 WO PCT/US2002/033875 patent/WO2003034996A2/en not_active Ceased
2003
- 2003-07-18 US US10/623,189 patent/US7183254B2/en active Active
2006
- 2006-11-29 US US11/606,805 patent/US20070099836A1/en not_active Abandoned
2010
- 2010-06-16 JP JP2010137501A patent/JP2010209114A/ja active Pending
2011
- 2011-05-09 US US13/103,294 patent/US8318666B2/en not_active Expired - Fee Related
2012
- 2012-11-05 US US13/669,324 patent/US20130190225A1/en not_active Abandoned
2014
- 2014-08-06 JP JP2014160718A patent/JP2014224142A/ja active Pending
2016
- 2016-05-13 US US15/154,749 patent/US20170095535A1/en not_active Abandoned
- 2016-05-31 JP JP2016108936A patent/JP2016190855A/ja not_active Withdrawn
- 2016-08-04 JP JP2016153889A patent/JP2016190872A/ja active Pending
2018
- 2018-07-27 JP JP2018141461A patent/JP6764906B2/ja not_active Expired - Lifetime
- 2018-11-19 US US16/195,661 patent/US20190321447A1/en not_active Abandoned
2019
- 2019-12-24 JP JP2019232609A patent/JP2020055868A/ja not_active Withdrawn
2020
- 2020-02-05 US US16/782,773 patent/US20200268853A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2016190855A (ja)	2016-11-10
EP2219031A1 (de)	2010-08-18
EP1444516A4 (de)	2006-05-10
PT2219031E (pt)	2013-05-17
ES2418954T3 (es)	2013-08-19
WO2003034996B1 (en)	2004-02-12
CA2464277A1 (en)	2003-05-01
US20170095535A1 (en)	2017-04-06
DK1444516T3 (da)	2010-11-15
EP2219031B1 (de)	2013-04-24
JP2018203744A (ja)	2018-12-27
WO2003034996A3 (en)	2003-12-11
MXPA04003773A (es)	2004-07-30
PL374301A1 (en)	2005-10-03
SI2219031T1 (sl)	2013-11-29
US7183254B2 (en)	2007-02-27
US8318666B2 (en)	2012-11-27
CA2464277C (en)	2013-02-05
US20130190225A1 (en)	2013-07-25
JP2005506994A (ja)	2005-03-10
JP2014224142A (ja)	2014-12-04
US20200268853A1 (en)	2020-08-27
US20190321447A1 (en)	2019-10-24
US20050020496A1 (en)	2005-01-27
JP2016190872A (ja)	2016-11-10
JP6764906B2 (ja)	2020-10-07
ES2350924T3 (es)	2011-01-28
JP2010209114A (ja)	2010-09-24
AU2002359288B2 (en)	2008-07-31
JP2020055868A (ja)	2020-04-09
DK2219031T3 (da)	2013-06-17
PL214862B1 (pl)	2013-09-30
WO2003034996A2 (en)	2003-05-01
EP1444516A2 (de)	2004-08-11
US20110306540A1 (en)	2011-12-15
EP1444516B1 (de)	2010-07-21
DE60237100D1 (de)	2010-09-02
US20070099836A1 (en)	2007-05-03

Legal Events

Date	Code	Title	Description
2011-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60237100D1 (de)	2010-09-02	Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
ATE510542T1 (de)	2011-06-15	Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE395357T1 (de)	2008-05-15	Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie
DE60227658D1 (de)	2008-08-28	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
DE60239612D1 (de)	2011-05-12	Monodisperse mischungen und verfahren zur behandlung von diabetes
ATE153696T1 (de)	1997-06-15	Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
ATE422357T1 (de)	2009-02-15	Verwendung von allopurinol zur behandlung von bluthochdruck
ATE377657T1 (de)	2007-11-15	Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
DE69836139D1 (de)	2006-11-23	Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE356995T1 (de)	2007-04-15	Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE69929787D1 (de)	2006-04-20	Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
ATE374618T1 (de)	2007-10-15	Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE338575T1 (de)	2006-09-15	Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
BR9912609A (pt)	2001-05-02	Métodos de uso de um análogo de somatostatina
DE69932922D1 (de)	2006-10-05	Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE60108130D1 (de)	2005-02-03	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE330596T1 (de)	2006-07-15	Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60141759D1 (de)	2010-05-20	Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
BR9914570A (pt)	2001-07-03	Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
DE69307702D1 (de)	1997-03-06	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE295731T1 (de)	2005-06-15	Olanzapine zur behandlung von drogenmissbrauch
JP2001187750A (ja)	2001-07-10	感染部位検知方法、それに使用する組成物およびその組成物の製造方法
CY1114326T1 (el)	2016-08-31	Χρηση της λεπτινης για τη θεραπεια της ανθρωπινης λιποατροφιας και μεθοδος καθορισμου της προδιαθεσης στην εν λογω θεραπευτικη αγωγη
ATE299021T1 (de)	2005-07-15	Verwendung von oxazolidinonderivaten zur behandlung von psoriasis